Abstract:Qi Kong, 1 Ling-ling Qian, 1 Lei Zhang, 1 Huan-huan Liu, 1, 2 Fan Yang, 1 Xiao-lu Zhang, 1 Chao Wang, 1 Xiao-xi Zhao, 1 Ku-lin Li, 1 Ru-xing Wang 1, 2 1 Department of Cardiology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, 214023, People's Republic of China; 2 Wuxi School of Medicine, Jiangnan University, Wuxi, 214122, People's Republic of China Correspondence: Ru-xing Wang; Ku-lin Li, Department of Cardiology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, 214023, People's Republic of China, Email ; Purpose: The aim of this study was to investigate the effects and mechanisms of SGLT2 inhibitor empagliflozin on diabetic coronary function. Methods: A rat diabetic model was established by injection of streptozotocin. Rats in the treated group were administered empagliflozin by gavage and rat coronary vascular tensions were measured after eight weeks. Large conductance calcium activated K + channel currents were recorded using a patch clamp technique, while human coronary artery smooth muscle cells were used to explore the underlying mechanisms. Results: After incubation with empagliflozin (10, 30, 100, 300, 1000 μmol/L), the Δ relaxation % of rat coronary arteries were 2.459 ± 1.304, 3.251 ± 1.119, 6.946 ± 3.407, 28.36 ± 11.47, 86.90 ± 3.868, respectively. Without and with empagliflozin in the bath solution, BK channel opening probabilities at a membrane potential of +60 mV were 0.0458 ± 0.0517 and 0.3413 ± 0.2047, respectively ( p < 0.05, n = 4 cells). After incubation with iberiotoxin, the Δ tensions of rat coronary arteries in the control (Ctrl), untreated (DM), low empagliflozin (10 mg/kg/d)-treated (DM+L-EMPA) and high empagliflozin (30mg/kg/d)-treated (DM+H-EMPA) group were 103.20 ± 5.85, 40.37 ± 22.12, 99.47 ± 28.51, 78.06 ± 40.98, respectively ( p < 0.01 vs Ctrl, n = 3– 7; p < 0.001 vs DM+L-EMPA, n = 5– 7). Empagliflozin restored high glucose-induced downregulation of Sirt1, Nrf2, and BK-β 1, while the effect of empagliflozin disappeared in the presence of EX-527, a Sirt1 selective inhibitor. Conclusion: Empagliflozin has a vasodilation effect on the coronary arteries in a concentration-dependent manner and can activate BK channels via the Sirt1-Nrf2 mechanism. Keywords: diabetes, SGLT2 inhibitor, vasodilatation, large conductance calcium activated potassium channel Diabetes mellitus (DM), as a chronic non-communicable disease, seriously harms human health. According to the World Health Organization, more than 3 million people worldwide die from diabetes mellitus and related complications each year, mainly from cardiovascular disease (CVD), especially with the most severe coronary vascular lesions. 1 Therefore, exploring the pathogenesis of diabetic coronary function and improving diabetic cardiovascular lesions are of great significance. Sodium-glucose co-transporter-2 (SGLT2) inhibitors are oral hypoglycemic drugs that reduce blood glucose level by inhibiting glucose re-absorption in the renal tubules. Representative drugs of this kind include empagliflozin (EMPA), canagliflozin, dapagliflozin, etc. In addition to glucose control, SGLT2 inhibitors have a wide range of cardiovascular benefits, including improving cardiac energy supply, reducing arterial stiffness, and inhibiting cardiac remodeling effects. 2–4 Recent studies have demonstrated that SGLT2 inhibitor is of great significance in vasodilation, independently of its hypoglycemic effect, which may be associated with K + channels on vascular smooth muscle cells (SMCs). 5,6 Large conductance calcium activated K + (BK) channel consists of four α subunits and four β subunits, 7 widely distributed in all tissues and cells of the human body, especially in vascular SMCs, and is one of the main K + channels on coronary artery SMCs. 8 Our previous study showed that, 9 BK channels regulate coronary artery relaxation, and BK channel function is impaired in diabetes mellitus. In this study, we aimed to examine the vasodilation of empagliflozin and the effect of empagliflozin on BK channels, exploring new mechanisms of the cardiovascular protection of SGLT2 inhibitors and providing a new clinical strategy for the management of cardiovascular complications in diabetes mellitus. Male Sprague Dawley (SD) rats (weight 180 ± 20g) were purchased from Changzhou Carvens Laboratory Animal Co., Ltd. in China. -Abstract Truncated-

Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK)

Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus

Metabolic cardio- and reno-protective effects of empagliflozin in a prediabetic rat model

Empagliflozin Enhances Autophagy, Mitochondrial Biogenesis, and Antioxidant Defense and Ameliorates Renal Ischemia/Reperfusion in Nondiabetic Rats

The SGLT2 Inhibitor, Empagliflozin, Attenuates Some Markers of Renal Fibrosis without Improving Albuminuria in Diabetic Db/Db Mice

SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease

Empagliflozin alleviates podocytopathy and enhances glomerular nephrin expression in db/db diabetic mice

Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice

Regression of diabetic nephropathy by treatment with empagliflozin in BTBR ob/ob mice.

Empagliflozin Ameliorates Type 2 Diabetes Mellitus-Related Diabetic Nephropathy Via Altering the Gut Microbiota

Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes

Empagliflozin alone and in combination with metformin mitigates diabetes-associated renal complications

Dapagliflozin can alleviate renal fibrosis in rats with streptozotocin‑induced type 2 diabetes mellitus

Novel insights into the effect of SGLT-2 inhibitor empagliflozin on hepatic damage in diabetic obese Zucker rats

Differential Effects of Empagliflozin on Microvascular Complications in Murine Models of Type 1 and Type 2 Diabetes

Nascent shifts in renal cellular metabolism, structure, and function due to chronic empagliflozin in prediabetic mice

Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats

[Empagliflozin inhibits inflammatory response and alleviates renal injury in type 2 diabetic rats by up-regulating the expression of exchange protein 1 directly activated by cAMP (Epac1)]

Empagliflozin Induces Vascular Relaxation in Rat Coronary Artery Due to Activation of BK Channels

Renal Effects of Empagliflozin in Patients with Type 2 Diabetes Mellitus

Empagliflozin reduces kidney fibrosis and improves kidney function by alternative macrophage activation in rats with 5/6-nephrectomy